Literature DB >> 21530767

The evolving role of bendamustine in lymphoid malignancy: understanding the drug and its mechanism of action--introduction.

Lorenzo M Leoni1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21530767     DOI： 10.1053/j.seminhematol.2011.03.001

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


× No keyword cloud information.
  2 in total

1.  Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.

Authors:  Dharshan Sivaraj; Michael M Green; Yubin Kang; Gwynn D Long; David A Rizzieri; Zhiguo Li; Anderson H Garrett; Jackie L McIntyre; Nelson J Chao; Cristina Gasparetto
Journal:  Blood Cancer J       Date:  2018-07-31       Impact factor: 11.037

2.  Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma.

Authors:  Binod Dhakal; Anita D'Souza; Mehdi Hamadani; Carlos Arce-Lara; Katrina Schroeder; Saurabh Chhabra; Nirav N Shah; Katelyn Gauger; Taylor Keaton; Marcelo Pasquini; Parameswaran Hari
Journal:  Blood Cancer J       Date:  2019-07-29       Impact factor: 11.037
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.